PMID- 32591923
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20210426
IS  - 1432-0991 (Electronic)
IS  - 0343-8651 (Linking)
VI  - 77
IP  - 10
DP  - 2020 Oct
TI  - In Vitro Studies on Therapeutic Potential of Probiotic Yeasts Isolated from 
      Various Sources.
PG  - 2821-2830
LID - 10.1007/s00284-020-02100-5 [doi]
AB  - The present study investigates the therapeutic properties of probiotic yeasts 
      viz. Yarrowia lipolytica VIT-MN01, Kluyveromyces lactis VIT-MN02, Lipomyces 
      starkeyi VIT-MN03, Saccharomycopsis fibuligera VIT-MN04 and Brettanomyces 
      custersianus VIT-MN05. The antimutagenic activity of probiotic yeasts against the 
      mutagens viz. Benzo[a]pyrene (B[a]P), and Sodium azide (SA) was tested. S. 
      fibuligera VIT-MN04 showed highest antimutagenicity (75%). Binding ability on the 
      mutagen acridine orange (AO) was tested and L. starkeyi VIT-MN03 was able to bind 
      AO effectively (88%). The probiotic yeasts were treated with the genotoxins viz. 
      4-Nitroquinoline 1-Oxide (NQO) and Methylnitronitrosoguanidine (MNNG). The 
      prominent changes in UV shift confirmed the reduction in genotoxic activity of S. 
      fibuligera VIT-MN04 and L. starkeyi VIT-MN03, respectively. Significant viability 
      of probiotic yeasts was noted after being exposed to mutagens and genotoxins. The 
      adhesion capacity and anticancer activity were also assessed using Caco-2 and 
      IEC-6 cell lines. Adhesion ability was found to be more in IEC-6 cells and 
      remarkable antiproliferative activity was noted in Caco-2 cells compared to 
      normal cells. Further, antagonistic activity of probiotic yeasts was investigated 
      against S. typhimurium which was found to be more in S. fibuligera VIT-MN04 and 
      L. starkeyi VIT-MN03. The inhibition of alpha-glucosidase and alpha-amylase activity 
      confirmed the antidiabetic activity of probiotic yeasts. Antioxidant activity was 
      also tested using standard assays. Therefore, based on the results, it can be 
      concluded that probiotic yeasts can serve as potential therapeutic agents for the 
      prevention and treatment of colon cancer, type 2 diabetes and gastrointestinal 
      infections.
FAU - Ragavan, Mangala Lakshmi
AU  - Ragavan ML
AD  - Department of Biomedical Sciences, School of Biosciences and Technology, Vellore 
      Institute of Technology, Vellore, Tamil Nadu, India.
FAU - Das, Nilanjana
AU  - Das N
AD  - Department of Biomedical Sciences, School of Biosciences and Technology, Vellore 
      Institute of Technology, Vellore, Tamil Nadu, India. nilanjanamitra@vit.ac.in.
LA  - eng
GR  - OMI- Fellowship/1/2019-ECD-1 & ID No. 2019-0420/Indian Council of Medical 
      Research/
PT  - Journal Article
DEP - 20200626
PL  - United States
TA  - Curr Microbiol
JT  - Current microbiology
JID - 7808448
RN  - Brettanomyces custersianus
RN  - Kluyveromyces lactis
RN  - Lipomyces starkeyi
RN  - Saccharomycopsis fibuligera
SB  - IM
MH  - Brettanomyces/physiology
MH  - Caco-2 Cells
MH  - Cell Line
MH  - Colonic Neoplasms/microbiology/therapy
MH  - Diabetes Mellitus, Type 2/microbiology/therapy
MH  - Humans
MH  - Kluyveromyces/physiology
MH  - Lipomyces/physiology
MH  - *Probiotics/therapeutic use
MH  - Saccharomycopsis/physiology
MH  - Yarrowia/physiology
MH  - *Yeasts/isolation & purification/physiology
EDAT- 2020/06/28 06:00
MHDA- 2021/04/27 06:00
CRDT- 2020/06/28 06:00
PHST- 2020/04/15 00:00 [received]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/06/28 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
PHST- 2020/06/28 06:00 [entrez]
AID - 10.1007/s00284-020-02100-5 [pii]
AID - 10.1007/s00284-020-02100-5 [doi]
PST - ppublish
SO  - Curr Microbiol. 2020 Oct;77(10):2821-2830. doi: 10.1007/s00284-020-02100-5. Epub 
      2020 Jun 26.